These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 22029186

  • 1. Estimating the cost of redundancy in molecular diagnostics: the case of activated protein C resistance and factor V Leiden.
    Rolla R, Vidali M, Meola S, Pollarolo P, Pergolini P, Bellomo G.
    Clin Lab; 2011; 57(9-10):711-7. PubMed ID: 22029186
    [Abstract] [Full Text] [Related]

  • 2. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
    Guasch JF, Lensen RP, Bertina RM.
    Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter C.
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
    Ivey LM, Thom JY, Ivey JG, Baker RI.
    Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
    [Abstract] [Full Text] [Related]

  • 8. Intraindividual consistency of the activated protein C resistance phenotype.
    Tosetto A, Simioni M, Madeo D, Rodeghiero F.
    Br J Haematol; 2004 Aug; 126(3):405-9. PubMed ID: 15257714
    [Abstract] [Full Text] [Related]

  • 9. The factor V (FV) gene ASP79HIS polymorphism modulates FV plasma levels and affects the activated protein C resistance phenotype in presence of the FV Leiden mutation.
    Bossone A, Cappucci F, D'Andrea G, Brancaccio V, Cibelli G, Iannaccone L, Grandone E, Margaglione M.
    Haematologica; 2003 Mar; 88(3):286-9. PubMed ID: 12651267
    [Abstract] [Full Text] [Related]

  • 10. A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
    De Bel AV, Van der Cruyssen GA, Devreese KM.
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):155-60. PubMed ID: 16479199
    [Abstract] [Full Text] [Related]

  • 11. Screening with the activated protein C resistance assay yields significant savings in a patient population with low prevalence of factor V leiden.
    Taylor LJ, Oster RA, Fritsma GA, Tichenor PH, Reed CE, Eiland BM, Hudson CL, Marques MB.
    Am J Clin Pathol; 2008 Mar; 129(3):494-9. PubMed ID: 18285275
    [Abstract] [Full Text] [Related]

  • 12. [Analysis of phenotype resistance to activated protein C (APC resistance)].
    Hudecek J, Ivanková J, Dobrotová M, Hybenová J, Pullmann R, Kubisz P.
    Vnitr Lek; 1999 Dec; 45(12):723-8. PubMed ID: 10951849
    [Abstract] [Full Text] [Related]

  • 13. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G, Valverde S.
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Factor V Leiden mutation in one family of Chinese origin.
    Wu J, Gu J, Xu J, Wang J, Sun Z, Smirnov MD, Morrissey JH, Esmon N.
    Chin Med J (Engl); 2001 Apr; 114(4):379-81. PubMed ID: 11780458
    [Abstract] [Full Text] [Related]

  • 17. Phenotyping and genotyping of coagulation factor V Leiden.
    Engel H, Zwang L, van Vliet HH, Michiels JJ, Stibbe J, Lindemans J.
    Thromb Haemost; 1996 Feb; 75(2):267-9. PubMed ID: 8815574
    [Abstract] [Full Text] [Related]

  • 18. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
    Zangari M, Berno T, Zhan F, Boucher KM, Tricot G, Fink L.
    Blood Coagul Fibrinolysis; 2011 Jul; 22(5):420-3. PubMed ID: 21537162
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
    Montes MA, Fox EA, Longtine JA, Dorfman DM.
    Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.